Shao Zhuyan, Fu Liying, Lu Yi, Zhou Haifei, Zhu Yuyang, Zhu Tao
Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Department of Clinical Nutrition, Zhejiang Cancer Hospital, Hangzhou, China.
Transl Cancer Res. 2025 May 30;14(5):3239-3254. doi: 10.21037/tcr-2025-758. Epub 2025 May 27.
Among gynecological malignancies, ovarian cancer is the most fatal, with surgery and chemotherapy being the primary treatment modalities. The nutritional status of patients with ovarian cancer undergoing chemotherapy after surgery remains generally poor, with 76.1% classified as severely malnourished according to the Patient-Generated Subjective Global Assessment (PG-SGA), while only 9.0% are well-nourished and do not require nutritional intervention. The high risk of nutritional decline associated with the new treatment modality, poly (ADP ribose) polymerase (PARP) inhibitors, has not received sufficient attention. This review examined the factors contributing to malnutrition in ovarian cancer, the adverse effects of malnutrition on treatment outcomes, the importance of regular nutritional screening and assessment, and potential nutritional interventions.
A review of the relevant literature was conducted to analyze the prevalence of malnutrition in patients with ovarian cancer, its impact on treatment and prognosis, and the role of nutritional assessment and interventions in improving patient outcomes.
Malnutrition is highly prevalent among patients with ovarian cancer and is associated with worsened treatment side effects, reduced quality of life, and decreased survival rates. The use of PARP inhibitors may pose an additional risk for nutritional decline, but this possibility has not been sufficiently studied. Regular nutritional screening and assessment are essential for the early detection and management of malnutrition. Nutritional interventions have been investigated for their potential to support patients with ovarian cancer through treatment, but further research is needed to determine the most effective strategies.
Malnutrition is a major concern for ovarian cancer patients, especially those receiving chemotherapy or PARP inhibitors. Regular nutritional assessment and timely interventions may improve treatment tolerance and overall prognosis. Further prospective studies and large randomized controlled trials are necessary to establish effective nutritional strategies for high-risk patients.
在妇科恶性肿瘤中，卵巢癌是最致命的，手术和化疗是主要的治疗方式。卵巢癌患者术后接受化疗时的营养状况普遍较差，根据患者主观全面评定法（PG-SGA），76.1%的患者被归类为严重营养不良，而只有9.0%的患者营养良好，不需要营养干预。与新的治疗方式聚（ADP核糖）聚合酶（PARP）抑制剂相关的营养下降高风险尚未得到充分关注。本综述探讨了导致卵巢癌患者营养不良的因素、营养不良对治疗结果的不良影响、定期营养筛查和评估的重要性以及潜在的营养干预措施。
对相关文献进行综述，以分析卵巢癌患者营养不良的发生率、其对治疗和预后的影响以及营养评估和干预在改善患者结局中的作用。
营养不良在卵巢癌患者中非常普遍，与治疗副作用加重、生活质量降低和生存率下降有关。使用PARP抑制剂可能会带来额外的营养下降风险，但这种可能性尚未得到充分研究。定期营养筛查和评估对于营养不良的早期发现和管理至关重要。已经对营养干预措施支持卵巢癌患者治疗的潜力进行了研究，但需要进一步研究以确定最有效的策略。
营养不良是卵巢癌患者的主要关注点，尤其是那些接受化疗或PARP抑制剂治疗的患者。定期营养评估和及时干预可能会提高治疗耐受性和总体预后。需要进一步的前瞻性研究和大型随机对照试验来为高危患者制定有效的营养策略。
